Literature DB >> 2522355

Exacerbation of toxic effects by endotoxin contamination of recombinant human tumor necrosis factor.

Y Ozaki1, T Oyama, S Kume.   

Abstract

The toxic effects of endotoxin-free human recombinant tumor necrosis factor (rH-TNF), shown to contain less than 50 pg endotoxin/mg rH-TNF, were investigated and compared with those of rH-TNF and endotoxin coadministered at 4-400 ng endotoxin/mg rH-TNF in female Sprague-Dawley rats. The mean lethal dose of 5.9 mg/kg rH-TNF found for the endotoxin-free rH-TNF was far higher than that attributed to rH-TNF by other investigators. Coadministration with endotoxin derived from E. Coli. Salmonella abortus equi, or Serratia marcescens reduced the apparent mean lethal dose of rH-TNF in correspondence to the endotoxin concentration, with a value of 0.7 mg/kg rH-TNF observed at 1600 ng, 757 ng, and 5260 ng endotoxin/mg rH-TNF, respectively. Coadministration also resulted in more severe histopathologic and physicochemical effects than rH-TNF alone. Histopathologic abnormalities observed only in coadministration included interlobular edema and hemorrhage of the pancreas and, most remarkably, splenomegaly, which was not observed with rH-TNF alone even at lethal doses. The results indicate that particular care in determining endotoxin contamination is essential in any consideration of TNF toxicity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2522355     DOI: 10.1007/bf00451647

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  18 in total

1.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.

Authors:  B Beutler; I W Milsark; A C Cerami
Journal:  Science       Date:  1985-08-30       Impact factor: 47.728

2.  Detection of tumour necrosis factor-like cytotoxicity in serum from patients with septicaemia but not from untreated cancer patients.

Authors:  A Waage; T Espevik; J Lamvik
Journal:  Scand J Immunol       Date:  1986-12       Impact factor: 3.487

3.  Molecular cloning of the gene encoding rabbit tumor necrosis factor.

Authors:  H Ito; T Shirai; S Yamamoto; M Akira; S Kawahara; C W Todd; R B Wallace
Journal:  DNA       Date:  1986-04

4.  Phase I study of recombinant tumor necrosis factor in cancer patients.

Authors:  M Blick; S A Sherwin; M Rosenblum; J Gutterman
Journal:  Cancer Res       Date:  1987-06-01       Impact factor: 12.701

5.  Limited effects of recombinant human and murine interleukin 1 and tumour necrosis factor on production of acute phase proteins by cultured rat hepatocytes.

Authors:  A Koj; A Kurdowska; D Magielska-Zero; H Rokita; J D Sipe; J M Dayer; S Demczuk; J Gauldie
Journal:  Biochem Int       Date:  1987-03

6.  Toxic effects of recombinant tumor necrosis factor in suckling mice. Comparisons with interferon alpha/beta.

Authors:  I Gresser; D Woodrow; J Moss; C Maury; J Tavernier; W Fiers
Journal:  Am J Pathol       Date:  1987-07       Impact factor: 4.307

7.  Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor.

Authors:  T Shirai; H Yamaguchi; H Ito; C W Todd; R B Wallace
Journal:  Nature       Date:  1985 Feb 28-Mar 6       Impact factor: 49.962

8.  Raised serum levels of tumour necrosis factor in parasitic infections.

Authors:  P Scuderi; K E Sterling; K S Lam; P R Finley; K J Ryan; C G Ray; E Petersen; D J Slymen; S E Salmon
Journal:  Lancet       Date:  1986-12-13       Impact factor: 79.321

9.  Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog.

Authors:  K J Tracey; S F Lowry; T J Fahey; J D Albert; Y Fong; D Hesse; B Beutler; K R Manogue; S Calvano; H Wei
Journal:  Surg Gynecol Obstet       Date:  1987-05

10.  Gamma interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors.

Authors:  M A Collart; D Belin; J D Vassalli; S de Kossodo; P Vassalli
Journal:  J Exp Med       Date:  1986-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.